78 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
statements regarding the potential benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
area: Audit, Compensation, and Nominating and Corporate Governance. Also, the Board will leverage feedback from its self-evaluation process, which … benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our arimoclomol expanded access program
424B3
u3gwywez8k
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
hhot6umbp9tobgevl58t
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
cvq5a7d7
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
xhxz7e
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
i5d401
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
ab3 n3rg68xx3e0
10 Nov 21
Prospectus supplement
5:19pm
424B3
zqvgtr9vahgojp
19 Oct 21
Prospectus supplement
9:27am